A great number of recent studies have demonstrated that lncRNAs contribute to cancer progression through numerous mechanisms; for example, by recruiting histone modification enzymes (such as EZH2, SUZ12, and LSD1) that repress or activate gene transcription [15, 16] acting as competing endogenous RNAs (ceRNAs) or sponges to inhibit microRNA (miRNA) activity [11], interacting with RNA-binding proteins (e.g., STAU1, UPF1, and hnRNPL) to regulate mRNA stability [10, 17, 18] and encoding small active peptide [19]. The gene discussed is EZH2; the disease is cancer.